Beta-blocker Heart Attack Trial PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Beta-blocker Heart Attack Trial PDF full book. Access full book title Beta-blocker Heart Attack Trial by National Institutes of Health (U.S.). Download full books in PDF and EPUB format.
Author: National Institutes of Health (U.S.)
Publisher:
ISBN:
Category : Adrenergic beta blockers
Languages : en
Pages : 12
Get Book
Book Description
Author: National Institutes of Health (U.S.)
Publisher:
ISBN:
Category : Adrenergic beta blockers
Languages : en
Pages : 12
Get Book
Book Description
Author: National Heart, Lung, and Blood Institute
Publisher:
ISBN:
Category : Adrenergic beta blockers
Languages : en
Pages : 56
Get Book
Book Description
Author: National Institutes of Health (U.S.)
Publisher:
ISBN:
Category :
Languages : en
Pages : 0
Get Book
Book Description
Author: Lawrence M. Friedman
Publisher: Mosby Elsevier Health Science
ISBN:
Category : Health & Fitness
Languages : en
Pages : 328
Get Book
Book Description
Author: John Malcolm Cruickshank, MD
Publisher: PMPH USA
ISBN: 1607952874
Category : Medical
Languages : en
Pages : 91
Get Book
Book Description
The Beta-Blocker Story: Getting it Right provides an essential guide for medical students and practitioners assessing patients for beta-blocker therapy. Using an evidence-based approach, the author, John Malcolm Cruickshank, provides readers with a thorough overview of beta-blocker use in the treatment of conditions such as ischemic heart disease, post-myocardial infarction, heart failure, dysrhythmias, and hypertension. The Beta-Blocker Story: Getting it Right received a 5-Star, 100 score from Doody's Review.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309282810
Category : Medical
Languages : en
Pages : 437
Get Book
Book Description
America's health care system has become too complex and costly to continue business as usual. Best Care at Lower Cost explains that inefficiencies, an overwhelming amount of data, and other economic and quality barriers hinder progress in improving health and threaten the nation's economic stability and global competitiveness. According to this report, the knowledge and tools exist to put the health system on the right course to achieve continuous improvement and better quality care at a lower cost. The costs of the system's current inefficiency underscore the urgent need for a systemwide transformation. About 30 percent of health spending in 2009-roughly $750 billion-was wasted on unnecessary services, excessive administrative costs, fraud, and other problems. Moreover, inefficiencies cause needless suffering. By one estimate, roughly 75,000 deaths might have been averted in 2005 if every state had delivered care at the quality level of the best performing state. This report states that the way health care providers currently train, practice, and learn new information cannot keep pace with the flood of research discoveries and technological advances. About 75 million Americans have more than one chronic condition, requiring coordination among multiple specialists and therapies, which can increase the potential for miscommunication, misdiagnosis, potentially conflicting interventions, and dangerous drug interactions. Best Care at Lower Cost emphasizes that a better use of data is a critical element of a continuously improving health system, such as mobile technologies and electronic health records that offer significant potential to capture and share health data better. In order for this to occur, the National Coordinator for Health Information Technology, IT developers, and standard-setting organizations should ensure that these systems are robust and interoperable. Clinicians and care organizations should fully adopt these technologies, and patients should be encouraged to use tools, such as personal health information portals, to actively engage in their care. This book is a call to action that will guide health care providers; administrators; caregivers; policy makers; health professionals; federal, state, and local government agencies; private and public health organizations; and educational institutions.
Author: Bertram Pitt
Publisher: Bailliere Tindall Limited
ISBN:
Category : Medical
Languages : en
Pages : 408
Get Book
Book Description
This text, aimed at the clinical cardiologist, covers the planning of and partcipation in a clinical trial. It interprets the importance of past clinical trials in current clinical practice.
Author: J. M. Cruickshank
Publisher: PMPH-USA
ISBN: 1607951088
Category : Adrenergic beta blockers
Languages : en
Pages : 286
Get Book
Book Description
The book provides a concise much-needed update of beta-blockers use cardiovascular area (particularly hypertension and heart failure). It will uncover the clinical inaccuracies of how the UK NICE Committee have "got it wrong" in their recent pronouncements on BBs and hypertension. Beta-blockers (BBs) are a large and important family of therapeutic agents with primary use is in cardiovascular medicine. The therapeutic areas that BB covers include: Ischemic Heart Disease, Hypertension, Heart Failure and Arrhythmias. Explanation of the role of BBs in the treatment of hypertension and why the UK Health Authority (The NICE Committee) have "got it wrong" A current update of the vital role of beta-blockers in the treatment of heart failure, and why some beta-blockers are "ineffective" Provides a total and current update of the role of beta-blockers in cardiovascular medicine.
Author: Michael Böhm
Publisher: Springer Science & Business Media
ISBN: 3642603009
Category : Medical
Languages : en
Pages : 299
Get Book
Book Description
Arterial hypertension, coronary heart disease and heart fail ure are the commonest cardiovascular conditions to present in clinical practice. Over the past few years it has become in creasingly clear that they are closely and causally interrelated and that their relationship can have a significant bearing on prognosis. Epidemiological studies have shown that arterial hypertension is one of the most important risk factors for de veloping heart failure. Only one in four patients with hyper tension is adequately managed, and in 50% of cases, the hypertension has not been recognised or treated. Patients with pre-existing hypertension who go on to suffer an acute myocardial infarction have usually not previously had typi cal angina symptoms, the infarct territory is larger, life threatening arrhythmias are commoner and hence in-hospi tal mortality and long-term prognosis are markedly worse. The presence of raised blood pressure in the post-infarct phase doubles the risk of manifest heart failure. The close relationship between hypertension, coronary heart disease and heart failure makes the choice of therapeu tic strategy particularly important. Agents and classes of agents that have prognostic value in all three conditions should be considered first, as synergy might result in addi tional benefits. In such patients, this sort of therapeutic deci sion-making might have further advantages. The use of these agents may prevent complications which are not yet clinically obvious (such as heart failure).
Author: Stephan Gielen
Publisher: European Society of Cardiology
ISBN: 0199656657
Category : Medical
Languages : en
Pages : 369
Get Book
Book Description
"EACPR, European Association for Cardiovascular Prevention and Rehabilitation -- European Society of Cardiology."
